Adalta Ltd. · ASX:1AD
Adalta — ANZ Biologics Festival 2026
21 slides from Adalta's conference presentation, Feb 4, 2026
Slide 1: Increasing patient access to CAR-T cell therapies in Australia and SE Asia
ASX Announcement | 4 February 2026 AdAlta Limited (ASX:1AD) Increasing patient access to CAR-T cell therapies in Australia and SE Asia: ANZ Biologics Festival presentation AdAlta Limited (ASX:1AD) (“AdAlta” or “the Company”), developer of next generation cell and protein therapeutic products is pres
Slide 2: AdAlta business model and company overview
AdAlta in-licenses products from Asian originators and invests to establish US FDA regulated manufacturing and conduct Phase I clinical studies with potential to position each product for on-licensing to larger biopharmaceutical companies for potential registrational studies and commercialization. A
Slide 3: Improving Patient Access to CAR-T Cell Therapy in Australia and SE Asia
For personal use only IMPROVING PATIENT ACCESS TO CAR-T CELL THERAPY IN AUSTRALIA AND SE ASIA Tim Oldham CEO and Managing Director, AdAlta Ltd ANZ Biologics Festival 4 Feb 2026 AdAlta Limited (ASX:1AD) | ANZ Festival of Biologics | February 2026 | 1
Slide 4: AdAlta: Next Generation Cell & Protein Therapeutics
ADALTA: NEXT GENERATION CELL & PROTEIN THERAPEUTICS “East to West” cellular immunotherapy strategy for growth For personal use only Bringing the potential of cellular immunotherapies to solid cancer AdAlta is - a clinical patients: 90% of cancers, untapped opportunity leveraging existing success in
Slide 5: Overview
OVERVIEW • CAR-T cell therapies are revolutionizing outcomes in cancer, autoimmune diseases and other fatal diseases For personal use only • However access to these groundbreaking therapies remains restricted, particularly in small markets like Australia, SE Asia ✗ Financial barriers include reimbur
Slide 6: CAR-T Therapies Are Revolutionizing Disease Outcomes
CAR-T THERAPIES ARE REVOLUTIONIZING DISEASE OUTCOMES 7 FDA-approved CAR-T For personal use only therapies for blood cancer Turbo-charging patient’s immune 2 FDA-approved T cell cells to “see” and Complete response rates:2 “kill” cancer therapies for solid cancer in 83% r/r pALL Living drug, single C
Slide 7: CAR-T Access Is Still Limited, Especially Outside US
CAR-T ACCESS IS STILL LIMITED, ESPECIALLY OUTSIDE US T cell therapies for oncology indications “Despite its curative potential … in the US, as well as in Product For personal use only European countries where CAR T-cell therapy is available to Kymriah (CD19 CAR-T, Novartis) 2017 2018 2021 2018 treat
Slide 8: Barriers to CAR-T Access
BARRIERS TO CAR-T ACCESS Deep dive topics • Opacity of system costs Financial - lack of For personal use only • Limited efficacy or durability data reimbursement/insurance • System not geared to "one-and-done" durable treatments Financial - margin pressure • High COGS limits commercial return to mos
Slide 9: CAR-T Challenges Traditional Reimbursement Models
CAR-T CHALLENGES TRADITIONAL REIMBURSEMENT MODELS For personal use only AdAlta Limited (ASX:1AD) | ANZ Festival of Biologics | February 2026 | 7 2025 Cell and Gene Therapy Report: Advancing the Future of Medicine,InspiroGene by McKesson
Slide 10: Total Cost to Deliver CAR-T Cell Therapy Is Substantial
TOTAL COST TO DELIVER CAR-T CELL THERAPY IS SUBSTANTIAL Total cost of CAR-T cell therapy delivery in the US typically ranges from $500,000 to over $1 million per patient For personal use only $373,000-$475,000 CAR-T product acquisition cost (list) $45,000-$600,000 Comprehensive care (apheresis, infu
Slide 11: Institutional Capacity Limits Access
INSTITUTIONAL CAPACITY LIMITS ACCESS For personal use only Up to 25% of eligible, approved patients do not receive therapy • Disease progression prior to product being available • Failed manufacturing AdAlta Limited (ASX:1AD) | ANZ Festival of Biologics | February 2026 | 9 2025 Cell and Gene Therapy
Slide 12: Actions to Improve Access in ANZ/ASEAN
ACTIONS TO IMPROVE ACCESS IN ANZ/ASEAN 1. Seeking/designing products for access For personal use only 2. Facilitate commercial product licensing 3. Increase clinical development: advantage Australia 4. Facilitate "home grown" product development - carefully 5. Implement value chain enablers AdAlta L
Slide 13: 1. Design Products for Access
1. DESIGN PRODUCTS FOR ACCESS* What can be done? Example: BZDS1901 aPD1-MSLN-CAR-T • Engineer features to enhance efficacy, durability and persistence For personal use only • Minimize conditioning regimens and adverse event (AE) profile ✓ Well established target • Shorten manufacturing and QC proces
Slide 14: 2. Commercial Product Licensing
2. COMMERCIAL PRODUCT LICENSING What can be done? Example: Selected products approved offshore but not available • Fill local product pipeline gaps here (including selected ex vivo gene therapies) For personal use only • License commercial products approved elsewhere for delivery in region • Replica
Slide 15: 3. Increase Clinical Development: Advantage Australia
3. INCREASE CLINICAL DEVELOPMENT: ADVANTAGE AUS What can be done? Example: AdCella’s “East to West” cellular immunotherapy strategy • Leverage Australia’s excellent cell and gene therapy ecosystem, For personal use only cost advantages and R&D Tax Incentive to make Australia an early destination for
Slide 16: 4. Facilitate Home Grown CAR-T Products - Carefully
4. FACILITATE “HOME GROWN” CAR-T PRODUCTS - CAREFULLY What can be done? Example: multiple countries experimenting with hospital • Enable academic/not for profit production of CAR-T products at exemption and “hub and spoke” manufacturing models For personal use only individual hospital centres for ad
Slide 17: 5. Value Chain Enablers
5. VALUE CHAIN ENABLERS Deep dive topics • CTN pathway for ex vivo gene modified cell therapies; conditional approvals Regulatory For personal use only • Reduced certification, risk management, monitoring requirements • Manufacturing flexibility: process ≠ product • Encourage early adoption of high
Slide 18: Regulatory Environment Moving in Favour of Adaptive Manufacturing Strategies
REGULATORY ENVIRONMENT MOVING IN FAVOUR OF ADAPTIVE MANUFACTURING STRATEGIES Regulators, industry historical mindset: “product is the process” For personal use only • Starting material is bigger driver of process outcomes than process itself What is the US FDA allowing? How does it impact the sector
Slide 19: Current Manufacturing Is the Bottleneck to Saving Lives
CURRENT MANUFACTURING IS THE BOTTLENECK TO SAVING LIVES FUTURE STATE • Future CAR-T processes are automated, less expensive, and very reproducible For personal use only CURRENT REALITY • Lower Cost of Goods (COGs): improves commercial viability • Existing CAR-T processes are manual, expensive, and h
Slide 20: A Blueprint for CAR-T Access?
A BLUEPRINT FOR CAR-T ACCESS? • CAR-T cell therapies are revolutionizing outcomes in cancer, autoimmune diseases and other fatal diseases For personal use only • However access to these groundbreaking therapies remains restricted, particularly in small markets like Australia, SE Asia ✗ Financial bar
Slide 21: For More Information Please Contact
For personal use only FOR MORE INFORMATION PLEASE CONTACT: TIM OLDHAM CEO & MANAGING DIRECTOR +61 403 446 665 [email protected] [email protected] WWW.ADALTA.COM.AU AdAlta Limited (ASX:1AD) | ANZ Festival of Biologics | February 2026 | 19